A detailed history of Citigroup Inc transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Citigroup Inc holds 5,234 shares of ABCL stock, worth $15,283. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,234
Previous 79,289 93.4%
Holding current value
$15,283
Previous $234,000 94.44%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$2.39 - $3.49 $176,991 - $258,451
-74,055 Reduced 93.4%
5,234 $13,000
Q2 2024

Aug 12, 2024

BUY
$2.73 - $4.73 $205,429 - $355,927
75,249 Added 1862.6%
79,289 $234,000
Q1 2024

May 10, 2024

SELL
$4.29 - $5.97 $17,434 - $24,262
-4,064 Reduced 50.15%
4,040 $18,000
Q4 2023

Feb 09, 2024

BUY
$3.91 - $5.93 $15,022 - $22,783
3,842 Added 90.15%
8,104 $46,000
Q3 2023

Nov 09, 2023

SELL
$4.6 - $7.95 $17,291 - $29,884
-3,759 Reduced 46.86%
4,262 $19,000
Q2 2023

Aug 10, 2023

BUY
$5.66 - $7.59 $16,323 - $21,889
2,884 Added 56.14%
8,021 $51,000
Q1 2023

May 11, 2023

SELL
$7.31 - $11.18 $18,508 - $28,307
-2,532 Reduced 33.02%
5,137 $38,000
Q4 2022

Feb 09, 2023

SELL
$9.48 - $14.52 $22,837 - $34,978
-2,409 Reduced 23.9%
7,669 $77,000
Q3 2022

Nov 10, 2022

SELL
$9.2 - $13.68 $208,343 - $309,797
-22,646 Reduced 69.2%
10,078 $100,000
Q2 2022

Aug 10, 2022

BUY
$5.72 - $10.65 $124,135 - $231,126
21,702 Added 196.9%
32,724 $349,000
Q1 2022

May 12, 2022

SELL
$7.46 - $14.14 $16,628 - $31,518
-2,229 Reduced 16.82%
11,022 $107,000
Q4 2021

Feb 10, 2022

BUY
$12.99 - $17.73 $97,048 - $132,460
7,471 Added 129.26%
13,251 $189,000
Q3 2021

Nov 10, 2021

BUY
$14.85 - $21.34 $85,833 - $123,345
5,780 New
5,780 $116,000

Others Institutions Holding ABCL

About AbCellera Biologics Inc.


  • Ticker ABCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 285,139,008
  • Market Cap $833M
  • Description
  • AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...
More about ABCL
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.